Logo image of TSVT

2SEVENTY BIO INC (TSVT) Stock Fundamental Analysis

NASDAQ:TSVT - Nasdaq - US9013841070 - Common Stock - Currency: USD

2.61  -0.07 (-2.61%)

Fundamental Rating

3

Taking everything into account, TSVT scores 3 out of 10 in our fundamental rating. TSVT was compared to 571 industry peers in the Biotechnology industry. TSVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TSVT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TSVT had negative earnings in the past year.
TSVT had a negative operating cash flow in the past year.
In the past 5 years TSVT always reported negative net income.
In the past 5 years TSVT always reported negative operating cash flow.
TSVT Yearly Net Income VS EBIT VS OCF VS FCFTSVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.77%, TSVT is in the better half of the industry, outperforming 79.32% of the companies in the same industry.
TSVT's Return On Equity of -41.45% is fine compared to the rest of the industry. TSVT outperforms 71.12% of its industry peers.
Industry RankSector Rank
ROA -18.77%
ROE -41.45%
ROIC N/A
ROA(3y)-38.55%
ROA(5y)-51.18%
ROE(3y)-82.77%
ROE(5y)-228.59%
ROIC(3y)N/A
ROIC(5y)N/A
TSVT Yearly ROA, ROE, ROICTSVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

TSVT's Gross Margin of 65.72% is amongst the best of the industry. TSVT outperforms 81.28% of its industry peers.
In the last couple of years the Gross Margin of TSVT has declined.
The Profit Margin and Operating Margin are not available for TSVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.27%
GM growth 5Y-3.3%
TSVT Yearly Profit, Operating, Gross MarginsTSVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

TSVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSVT has been increased compared to 1 year ago.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TSVT Yearly Shares OutstandingTSVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
TSVT Yearly Total Debt VS Total AssetsTSVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

TSVT has an Altman-Z score of -1.64. This is a bad value and indicates that TSVT is not financially healthy and even has some risk of bankruptcy.
TSVT has a Altman-Z score (-1.64) which is in line with its industry peers.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.64
ROIC/WACCN/A
WACC9.51%
TSVT Yearly LT Debt VS Equity VS FCFTSVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M -200M

2.3 Liquidity

TSVT has a Current Ratio of 4.95. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
TSVT has a Current ratio (4.95) which is in line with its industry peers.
TSVT has a Quick Ratio of 4.95. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.95, TSVT perfoms like the industry average, outperforming 54.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.95
Quick Ratio 4.95
TSVT Yearly Current Assets VS Current LiabilitesTSVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

TSVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.01%, which is quite impressive.
The Revenue for TSVT has decreased by -68.73% in the past year. This is quite bad
Measured over the past years, TSVT shows a quite strong growth in Revenue. The Revenue has been growing by 12.95% on average per year.
EPS 1Y (TTM)47.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81%
Revenue 1Y (TTM)-68.73%
Revenue growth 3Y-26.04%
Revenue growth 5Y12.95%
Sales Q2Q%12.46%

3.2 Future

Based on estimates for the next years, TSVT will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.90% on average per year.
The Revenue is expected to decrease by -4.31% on average over the next years.
EPS Next Y74.63%
EPS Next 2Y37.79%
EPS Next 3Y25.32%
EPS Next 5Y16.9%
Revenue Next Year-54.72%
Revenue Next 2Y-21.04%
Revenue Next 3Y-6.95%
Revenue Next 5Y-4.31%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TSVT Yearly Revenue VS EstimatesTSVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
TSVT Yearly EPS VS EstimatesTSVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TSVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSVT Price Earnings VS Forward Price EarningsTSVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSVT Per share dataTSVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as TSVT's earnings are expected to grow with 25.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.79%
EPS Next 3Y25.32%

More info and screens

0

5. Dividend

5.1 Amount

TSVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

2SEVENTY BIO INC

NASDAQ:TSVT (2/21/2025, 8:00:01 PM)

2.61

-0.07 (-2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-17 2025-03-17/amc
Inst Owners89.58%
Inst Owner Change-90.18%
Ins Owners4.73%
Ins Owner Change2.55%
Market Cap134.65M
Analysts76.67
Price Target6.63 (154.02%)
Short Float %10.82%
Short Ratio15.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.44%
Min EPS beat(2)22.77%
Max EPS beat(2)168.1%
EPS beat(4)2
Avg EPS beat(4)39.76%
Min EPS beat(4)-21.92%
Max EPS beat(4)168.1%
EPS beat(8)6
Avg EPS beat(8)32.74%
EPS beat(12)9
Avg EPS beat(12)19.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.91%
Min Revenue beat(2)-38.07%
Max Revenue beat(2)-11.76%
Revenue beat(4)0
Avg Revenue beat(4)-23.01%
Min Revenue beat(4)-38.07%
Max Revenue beat(4)-11.76%
Revenue beat(8)2
Avg Revenue beat(8)22.43%
Revenue beat(12)4
Avg Revenue beat(12)10.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.7%
PT rev (3m)-21.21%
EPS NQ rev (1m)-40.41%
EPS NQ rev (3m)27.63%
EPS NY rev (1m)-3.61%
EPS NY rev (3m)-6.7%
Revenue NQ rev (1m)-22.33%
Revenue NQ rev (3m)-47.57%
Revenue NY rev (1m)-1.05%
Revenue NY rev (3m)-13.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.95
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-1.86
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-2.73
FCFYN/A
OCF(TTM)-2.7
OCFYN/A
SpS0.88
BVpS4.42
TBVpS4.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.77%
ROE -41.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.72%
FCFM N/A
ROA(3y)-38.55%
ROA(5y)-51.18%
ROE(3y)-82.77%
ROE(5y)-228.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.27%
GM growth 5Y-3.3%
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.05%
Cap/Sales 3.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.95
Quick Ratio 4.95
Altman-Z -1.64
F-Score3
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)150.89%
Cap/Depr(5y)219.23%
Cap/Sales(3y)24.9%
Cap/Sales(5y)43.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81%
EPS Next Y74.63%
EPS Next 2Y37.79%
EPS Next 3Y25.32%
EPS Next 5Y16.9%
Revenue 1Y (TTM)-68.73%
Revenue growth 3Y-26.04%
Revenue growth 5Y12.95%
Sales Q2Q%12.46%
Revenue Next Year-54.72%
Revenue Next 2Y-21.04%
Revenue Next 3Y-6.95%
Revenue Next 5Y-4.31%
EBIT growth 1Y24.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.65%
EBIT Next 3Y25.33%
EBIT Next 5YN/A
FCF growth 1Y45.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.54%
OCF growth 3YN/A
OCF growth 5YN/A